Market Summary
USD116.45-0.45
Market Closed-0.38%
ICUI Stock Price
ICUI RSI Chart
ICUI Valuation
ICUI Price/Sales (Trailing)
ICUI Profitability
ICUI Fundamentals
ICUI Revenue
ICUI Earnings
Price Action
52 Week Range
115.33212.43
(Low)(High)
Last 7 days
-9.0%
Last 30 days
-15.6%
Last 90 days
-33.9%
Trailing 12 Months
-23.4%
ICUI Financial Health
ICUI Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for ICUI
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-08 | Voigtlander Christian B. | sold | -883,930 | 129 | -6,850 | chief operating officer |
2023-07-12 | Jain Vivek | sold | -5,400,720 | 180 | -30,000 | chairman and ceo |
2023-07-12 | Jain Vivek | acquired | 1,763,700 | 58.79 | 30,000 | chairman and ceo |
2023-06-14 | Jain Vivek | sold | -5,660,090 | 188 | -30,000 | chairman and ceo |
2023-06-14 | Jain Vivek | acquired | 1,763,700 | 58.79 | 30,000 | chairman and ceo |
2023-06-07 | FINNEY ELISHA W | sold | -36,939 | 190 | -194 | - |
2023-06-02 | Jain Vivek | gifted | - | - | -85.00 | chairman and ceo |
2023-05-17 | Greenberg David C. | acquired | - | - | 485 | - |
2023-05-17 | Abbey Donald | acquired | - | - | 485 | - |
2023-05-17 | Hoffmeister David F | acquired | - | - | 485 | - |
Which funds bought or sold ICUI recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-20 | BARCLAYS PLC | reduced | -18.07 | -1,276,000 | 9,814,000 | 0.01% |
2023-09-18 | WASHINGTON CAPITAL MANAGEMENT, INC | unchanged | - | 38,367 | 516,751 | 0.44% |
2023-09-12 | Farther Finance Advisors, LLC | new | - | 535 | 535 | -% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | 543 | 7,306 | -% |
2023-08-23 | WOLVERINE TRADING, LLC | new | - | 832,066 | 832,066 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | new | - | 534,570 | 534,570 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.65 | 216,683 | 4,415,900 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 8.93 | 26,641 | 180,251 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 10.87 | 99,000 | 598,000 | 0.01% |
2023-08-21 | BOKF, NA | reduced | -38.34 | -20,546 | 40,984 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of ICU Medical
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | t. rowe price investment management, inc. | 10.1% | 2,423,228 | SC 13G/A | |
| Feb 10, 2023 | janus henderson group plc | 10.7% | 2,557,226 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.77% | 2,104,172 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 9.87% | 2,366,386 | SC 13G | |
| Jan 31, 2023 | blackrock inc. | 7.5% | 1,787,807 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 12.8% | 2,725,540 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 9.18% | 1,950,253 | SC 13G/A | |
| Feb 10, 2022 | janus henderson group plc | 10.8% | 2,294,880 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.9% | 1,686,855 | SC 13G/A | |
| Jan 12, 2022 | smiths group international holdings ltd | 10.5% | 2,500,000 | SC 13D |
Recent SEC filings of ICU Medical
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 11, 2023 | 4 | Insider Trading | |
| Sep 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 07, 2023 | 8-K | Current Report | |
| Aug 07, 2023 | 10-Q | Quarterly Report | |
| Jul 14, 2023 | 4 | Insider Trading | |
| Jul 12, 2023 | 144 | Notice of Insider Sale Intent | |
| Jun 15, 2023 | 4 | Insider Trading | |
| Jun 14, 2023 | 144 | Notice of Insider Sale Intent |
ICUI Fair Value
Loading...
Peers (Alternatives to ICU Medical)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
SYK | 108.3B | 19.5B | 3.38% | 36.58% | 39.99 | 5.57 | 10.36% | 30.30% |
ISRG | 101.2B | 6.7B | -0.75% | 50.83% | 71.05 | 15.19 | 11.75% | -0.66% |
BSX | 77.5B | 13.4B | 6.45% | 36.39% | 85 | 5.78 | 8.69% | 3.17% |
BDX | 71.3B | 19.0B | -4.29% | 12.66% | 44.09 | 3.79 | 0.46% | -5.24% |
EW | 42.3B | 5.7B | -8.22% | -17.24% | 30.48 | 7.49 | 5.64% | -4.53% |
| MID-CAP | ||||||||
PEN | 9.5B | 937.8M | -2.12% | 37.22% | 325.65 | 10.11 | 16.30% | 250.21% |
SWAV | 7.1B | 616.6M | -12.54% | -24.86% | 29.24 | 11.56 | 69.52% | 343.68% |
GMED | 5.1B | 1.1B | -6.10% | -12.07% | 24.23 | 4.65 | 12.63% | 50.85% |
IRTC | 2.6B | 452.1M | -21.20% | -33.94% | -26.32 | 5.78 | 24.99% | 24.09% |
TNDM | 1.3B | 790.3M | -27.09% | -56.49% | -5.97 | 1.69 | 3.21% | -1604.53% |
| SMALL-CAP | ||||||||
ATEC | 1.6B | 421.8M | -15.15% | 56.11% | -9.32 | 3.69 | 44.49% | -2.43% |
AVNS | 947.4M | 780.7M | -7.75% | -9.65% | -26.32 | 1.21 | 4.68% | -510.17% |
CSII | 839.3M | 239.8M | 0.70% | 0.15% | -22.16 | 3.5 | -4.74% | -31.15% |
SILK | 609.7M | 162.9M | -27.67% | -61.65% | -11.53 | 3.74 | 42.67% | 12.82% |
ICU Medical News
Returns for ICUI
Cumulative Returns on ICUI
5.5%
10-Year Cumulative Returns
-1.2%
7-Year Cumulative Returns
-15.2%
5-Year Cumulative Returns
-15.0%
3-Year Cumulative Returns
Risks for ICUI
What is the probability of a big loss on ICUI?
78.1%
Probability that ICU Medical stock will be more than 20% underwater in next one year
53.1%
Probability that ICU Medical stock will be more than 30% underwater in next one year.
29.6%
Probability that ICU Medical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ICUI drawdown profile look like?
Y-axis is the maximum loss one would have experienced if ICU Medical was unfortunately bought at previous high price.
Drawdowns
Financials for ICU Medical
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -0.5% | 2,294 | 2,306 | 2,280 | 2,043 | 1,781 | 1,541 | 1,316 | 1,296 | 1,279 | 1,260 | 1,271 | 1,266 | 1,255 | 1,264 | 1,266 | 1,291 | 1,311 | 1,359 | 1,400 | 1,430 | 1,446 |
| Gross Profit | 3.4% | 746 | 721 | 698 | 650 | 592 | 548 | 491 | 484 | 470 | 453 | 461 | 456 | 460 | 458 | 472 | 492 | 508 | 556 | 570 | 573 | 550 |
| Operating Expenses | 3.1% | 734 | 712 | 741 | 669 | 572 | 493 | 368 | 357 | 356 | 354 | 363 | 367 | 364 | 355 | 365 | 412 | 459 | 501 | 540 | 491 | 474 |
| S&GA Expenses | -1.3% | 600 | 608 | 608 | 547 | 468 | 383 | 303 | 295 | 291 | 284 | 284 | 281 | 276 | 277 | 277 | 283 | 294 | 308 | 320 | 319 | 319 |
| R&D Expenses | -0.3% | 89.00 | 89.00 | 93.00 | 83.00 | 72.00 | 61.00 | 47.00 | 46.00 | 44.00 | 43.00 | 43.00 | 44.00 | 46.00 | 47.00 | 49.00 | 50.00 | 51.00 | 53.00 | 53.00 | 53.00 | 53.00 |
| EBITDA | -100.0% | - | 112 | - | 130 | 151 | 159 | 221 | 219 | 207 | 193 | 185 | 174 | 178 | 181 | 192 | 159 | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.05* | - | 0.06* | 0.08* | 0.10* | 0.17* | 0.17* | 0.16* | 0.15* | 0.15* | 0.14* | 0.14* | 0.14* | 0.15* | 0.12* | - | - | - | - | - |
| Interest Expenses | 14.9% | -49.66 | -58.34 | -66.37 | 51.00 | 30.00 | 15.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Earnings Before Taxes | -11.7% | -76.75 | -68.73 | - | -123 | -44.97 | 24.00 | - | 130 | 118 | 104 | 97.00 | 88.00 | 95.00 | 102 | 115 | 81.00 | 50.00 | 52.00 | 22.00 | 75.00 | 78.00 |
| EBT Margin | 100.0% | - | -0.03* | - | -0.06* | -0.03* | 0.02* | 0.10* | 0.10* | 0.09* | 0.08* | 0.08* | 0.07* | 0.08* | 0.08* | 0.09* | 0.06* | - | - | - | - | - |
| Net Income | -5.3% | -48.49 | -46.03 | -74.29 | -38.83 | 5.00 | 41.00 | 103 | 109 | 103 | 94.00 | 87.00 | 81.00 | 83.00 | 87.00 | 101 | 73.00 | 47.00 | 55.00 | 29.00 | 86.00 | 86.00 |
| Net Income Margin | 100.0% | - | -0.02* | -0.03* | -0.02* | 0.00* | 0.03* | 0.08* | 0.08* | 0.08* | 0.07* | 0.07* | 0.06* | 0.07* | 0.07* | 0.08* | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -100 | -152 | -68.59 | 12.00 | 137 | 199 | 187 | 177 | 154 | 131 | 107 | 81.00 | 68.00 | 5.00 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.2% | 4,463 | 4,471 | 4,516 | 4,450 | 4,590 | 4,747 | 1,881 | 1,839 | 1,803 | 1,765 | 1,764 | 1,730 | 1,859 | 1,817 | 1,692 | 1,638 | 1,623 | 1,613 | 1,585 | 1,545 | 1,526 |
| Current Assets | 2.6% | 1,245 | 1,213 | 1,235 | 1,199 | 1,190 | 1,174 | 1,030 | 1,011 | 973 | 928 | 921 | 900 | 1,037 | 1,002 | 882 | 944 | 930 | 921 | 927 | 913 | 900 |
| Cash Equivalents | -11.3% | 196 | 221 | 209 | 244 | 256 | 329 | 553 | 519 | 462 | 424 | 396 | 351 | 446 | 420 | 269 | 316 | 292 | 296 | 345 | 319 | 309 |
| Inventory | 3.7% | 775 | 748 | 696 | 625 | 583 | 536 | 290 | 292 | 300 | 300 | 315 | 322 | 323 | 312 | 338 | 344 | 330 | 322 | 311 | 292 | 289 |
| Net PPE | -1.2% | 617 | 624 | 636 | 656 | 668 | 674 | 468 | 458 | 459 | 459 | 467 | 456 | 455 | 456 | 456 | 444 | 437 | 433 | 433 | 425 | 416 |
| Goodwill | 0.1% | 1,464 | 1,463 | 1,449 | 1,370 | 1,421 | 1,527 | 43.00 | 33.00 | 33.00 | 33.00 | 33.00 | 33.00 | 32.00 | 31.00 | 31.00 | 11.00 | 11.00 | 11.00 | 11.00 | 13.00 | 13.00 |
| Current Liabilities | 4.7% | 484 | 462 | 495 | 489 | 486 | 494 | 201 | 185 | 184 | 180 | 195 | 185 | 359 | 357 | 248 | 255 | 260 | 238 | 249 | 203 | 202 |
| LT Debt, Current | 15.1% | 40.00 | 35.00 | 30.00 | 24.00 | 19.00 | 14.00 | - | - | - | - | - | - | 150 | 150 | - | - | - | - | - | - | - |
| LT Debt, Non Current | -0.7% | 1,601 | 1,612 | 1,624 | 1,630 | 1,636 | 1,642 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | 0.7% | 2,115 | 2,100 | 2,090 | 2,013 | 2,086 | 2,179 | 1,616 | 1,590 | 1,557 | 1,521 | 1,502 | 1,452 | 1,412 | 1,376 | 1,377 | 1,340 | 1,318 | 1,283 | 1,264 | 1,260 | 1,257 |
| Retained Earnings | -1.2% | 818 | 828 | 838 | 853 | 866 | 874 | 912 | 892 | 861 | 832 | 809 | 783 | 758 | 739 | 722 | 701 | 675 | 652 | 621 | 628 | 628 |
| Additional Paid-In Capital | 0.4% | 1,345 | 1,340 | 1,331 | 1,323 | 1,310 | 1,306 | 721 | 711 | 706 | 702 | 693 | 683 | 675 | 666 | 669 | 660 | 658 | 660 | 658 | 652 | 644 |
| Shares Outstanding | 0.2% | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 20.00 | 20.00 | 20.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 306.6% | 40.00 | -19.54 | -62.13 | 22.00 | 99.00 | 215 | 268 | 263 | 260 | 235 | 223 | 193 | 168 | 162 | 102 | 103 | 104 | 160 | 160 | 195 | 242 |
| Share Based Compensation | 6.1% | 35.00 | 33.00 | 36.00 | 37.00 | 34.00 | 33.00 | 27.00 | 25.00 | 24.00 | 23.00 | 24.00 | 24.00 | 22.00 | 23.00 | 22.00 | 22.00 | 25.00 | 25.00 | 24.00 | 24.00 | 22.00 |
| Cashflow From Investing | -21.8% | -69.31 | -56.90 | -1,909 | -1,918 | -1,926 | -1,939 | -90.69 | -98.65 | -101 | -93.55 | -98.14 | -158 | -158 | -179 | -166 | -84.97 | -106 | -98.86 | -103 | -113 | -119 |
| Cashflow From Financing | -6.7% | -29.59 | -27.72 | 1,637 | 1,632 | 1,631 | 1,635 | -16.87 | 3.00 | -146 | -141 | -0.04 | -1.13 | 148 | 145 | -10.91 | -14.31 | -13.37 | -7.03 | 8.00 | -54.98 | -45.81 |
| Buy Backs | - | - | - | 11.00 | - | - | - | 8.00 | - | - | - | 13.00 | - | - | - | 19.00 | - | - | - | 6.00 | - | 6.00 |
ICUI Income Statement
2023-06-30Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| REVENUES: | ||||
| Revenue from Contract with Customer, Excluding Assessed Tax | $ 549,310 | $ 561,004 | $ 1,117,959 | $ 1,104,126 |
| Cost of goods sold | 356,983 | 393,411 | 733,591 | 767,706 |
| Gross Profit | 192,327 | 167,593 | 384,368 | 336,420 |
| OPERATING EXPENSES: | ||||
| Selling, general and administrative | 150,895 | 158,748 | 303,467 | 311,960 |
| Research and development | 22,302 | 22,562 | 42,063 | 46,433 |
| Restructuring, strategic transaction and integration | 12,354 | 13,525 | 23,367 | 47,430 |
| Change in fair value of contingent earn-out | 4,016 | (27,194) | 3,316 | (27,194) |
| TOTAL OPERATING EXPENSES | 189,567 | 167,641 | 372,213 | 378,629 |
| (LOSS) INCOME FROM OPERATIONS | 2,760 | (48) | 12,155 | (42,209) |
| Interest Expense | (24,121) | (15,440) | (46,636) | (28,495) |
| OTHER (EXPENSE) INCOME, net | (1,502) | (1,366) | (1,771) | (951) |
| (Loss) Income from Continuing Operations before Income Taxes, Noncontrolling Interest | (22,863) | (16,854) | (36,252) | (71,655) |
| BENEFIT (PROVISION) FOR INCOME TAXES | 12,929 | 9,380 | 16,506 | 26,113 |
| NET (LOSS) INCOME | $ (9,934) | $ (7,474) | $ (19,746) | $ (45,542) |
| NET INCOME PER SHARE | ||||
| Basic (in dollars per share) | $ (0.41) | $ (0.31) | $ (0.82) | $ (1.91) |
| Diluted (in dollars per share) | $ (0.41) | $ (0.31) | $ (0.82) | $ (1.91) |
| WEIGHTED AVERAGE NUMBER OF SHARES | ||||
| Basic (in shares) | 24,075 | 23,897 | 24,045 | 23,787 |
| Diluted (in shares) | 24,075 | 23,897 | 24,045 | 23,787 |
ICUI Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | |||
|---|---|---|---|---|---|
| CURRENT ASSETS: | |||||
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $ 195,887 | $ 208,784 | [1] | ||
| Short-term investment securities | 1,812 | 4,224 | [1] | ||
| TOTAL CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES | 197,699 | 213,008 | [1] | ||
| Accounts receivable, net of allowance for doubtful accounts | 162,225 | 221,719 | [1] | ||
| Inventories | 775,269 | 696,009 | [1] | ||
| Prepaid income taxes | 13,766 | 15,528 | [1] | ||
| Prepaid expenses and other current assets | 95,783 | 88,932 | [1] | ||
| TOTAL CURRENT ASSETS | 1,244,742 | 1,235,196 | [1] | ||
| PROPERTY AND EQUIPMENT, net | 616,540 | 636,113 | [1] | ||
| Operating Lease, Right-of-Use Asset | 76,028 | 74,864 | [1] | ||
| Long-term investment securities | 0 | 516 | |||
| GOODWILL | 1,464,478 | 1,449,258 | [1] | ||
| INTANGIBLE ASSETS, net | 929,830 | 982,766 | [1] | ||
| Deferred Income Tax Assets | 31,466 | 31,466 | |||
| OTHER ASSETS | 99,960 | 105,462 | [1] | ||
| TOTAL ASSETS | 4,463,044 | 4,515,641 | [1] | ||
| CURRENT LIABILITIES: | |||||
| Accounts payable | 167,054 | 215,902 | [1] | ||
| Accrued liabilities | 254,508 | 242,769 | [1] | ||
| Long-term Debt, Current Maturities | 40,375 | 29,688 | |||
| Income tax liability | 19,954 | 6,200 | [1] | ||
| Contingent earn-out liability | 1,989 | 0 | |||
| TOTAL CURRENT LIABILITIES | 483,880 | 494,559 | [1] | ||
| Contingent Earn-Out Liability, Noncurrent | 26,944 | 25,572 | [1] | ||
| Long-term Debt, Excluding Current Maturities | 1,600,720 | 1,623,675 | |||
| Other long-term liabilities | 109,858 | 114,104 | |||
| DEFERRED INCOME TAXES | 89,684 | 126,007 | [1] | ||
| INCOME TAX LIABILITY | 37,140 | 41,796 | [1] | ||
| COMMITMENTS AND CONTINGENCIES | 0 | 0 | [1] | ||
| STOCKHOLDERS' EQUITY: | |||||
| Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none | 0 | 0 | [1] | ||
| Common stock, $0.10 par value - Authorized-80,000 shares | 2,411 | 2,399 | [1] | ||
| Additional paid-in capital | 1,345,057 | 1,331,249 | [1] | ||
| Treasury Stock, at cost | (1,611) | (243) | [1] | ||
| Retained earnings | 817,755 | 837,501 | [1] | ||
| Accumulated other comprehensive loss | (48,794) | (80,978) | [1] | ||
| TOTAL STOCKHOLDERS' EQUITY | 2,114,818 | 2,089,928 | [1] | ||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 4,463,044 | $ 4,515,641 | [1] | ||
| |||||
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.